What type of study is this?

Targeted regulatory T cell activation by site-specific PEGylated interleukin-2 mitigates autoimmune inflammation

View Full Paper

Ask AI

Bookmark

Authors

Novel IL-2 variant I129-W80 selectively activates Tregs, improving autoimmune conditions, suggesting enhanced treatment options.

I129-W80 improved inflammatory responses in autoimmune disease models, showing promise as a novel treatment strategy.
In monkey studies, I129-W80 demonstrated longer half-life and sustained Treg activation compared to existing IL-2 variants.
Site-specific PEGylation of IL-2 enhances Treg selectivity, minimizing adverse effects associated with broader immune activation.
This study highlights the potential of I129-W80 in correcting immune imbalances due to Treg dysfunction in autoimmune diseases.

Ikeda et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark